LabGenius Therapeutics
Generated by Meeveem AI
"Pioneering machine learning driven antibody discovery for next generation cancer therapeutics"
London
•51 - 250 Employees
•Biotechnology
About LabGenius Therapeutics
LabGenius Therapeutics develops therapeutic antibodies by combining machine learning, synthetic biology and robotic automation. Complex antibodies like multispecifics are difficult to engineer because design and function relationships are non-intuitive, leading to molecules that fail or deliver poor outcomes. Its EVA™ platform integrates high throughput experimentation with machine learning, enabling rapid co-optimisation across multiple properties. LabGenius focuses on selectivity enhanced antibodies for solid tumours, using avidity to differentiate healthy and diseased cells. This delivers complete killing selectivity, minimising on-target off-tumour toxicity that plagues conventional therapies and limits cancer treatment options.
68
Team Members
2012
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where cancer patients receive highly selective, effective therapies designed by intelligent systems that eliminate tumours without harming healthy tissue, ending preventable treatment failures and toxicity.
Our Mission
At LabGenius, our mission is to accelerate the discovery of next generation therapeutic antibodies.